CLASS ACTION UPDATE for INNV, HEPS and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / November 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

INNV Shareholders Click Here: https://www.zlk.com/pslra-1/innovage-holding-inc-loss-submission-form-2?prid=21171&wire=1
HEPS Shareholders Click Here: https://www.zlk.com/pslra-1/d-market-elektronik-hizmetler-ve-ticaret-anonim-irketi-a-k-a-d-market-electronic-services-trading-d-b-a-hepsiburada-information-request-form?prid=21171&wire=1
BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21171&wire=1

* ADDITIONAL INFORMATION BELOW *

InnovAge Holding Inc. (NASDAQ:INNV)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired InnovAge common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.
Lead Plaintiff Deadline : December 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/innovage-holding-inc-loss-submission-form-2?prid=21171&wire=1

According to the filed complaint, (1) certain of InnovAge's facilities failed to provide covered services, provide accessible and adequate services, manage participants' medical situations, and oversee use of specialists; (2) as a result, the Company was reasonably likely to be subject to regulatory scrutiny, including by the Centers for Medicare and Medicaid Services; (3) as a result, there as a significant risk that CMS would suspend new enrollments pending an audit of the Company's services; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

D-MARKET Elektronik Hizmetler ve Ticaret Anonim irketi a/k/a D-MARKET Electronic Services & Trading d/b/a/ Hepsiburada (NASDAQ:HEPS)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Hepsiburada American Depositary Receipts ("ADRs") pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's July 2021 initial public offering.
Lead Plaintiff Deadline : December 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/d-market-elektronik-hizmetler-ve-ticaret-anonim-irketi-a-k-a-d-market-electronic-services-trading-d-b-a-hepsiburada-information-request-form?prid=21171&wire=1

According to the filed complaint, (1) Hepsiburada suffered a sharp deceleration in operational and sales growth during second quarter 2021; (2) as a result, the Company initiated certain actions to fortify its competitive position, including investing in electronics and high frequency categories and discounting certain categories; (3) as a result of the foregoing, Hepsiburada's revenue and Gross Merchandise Value had declined during second quarter 2021; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BMRN Lawsuit on behalf of: investors who purchased January 13, 2020 - September 3, 2021
Lead Plaintiff Deadline : December 22, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21171&wire=1

According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP